Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02930824 · ClinicalTrials.gov registry record · NA
Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing
A NA study, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 185
- Enrollment target
NCT02930824 is a NA study that has completed, run by University of Florida. The registered enrollment target is 185 participants.
The verdict
NCT02930824, a NA study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 185 participants
- Enrollment target
Study Summary
Investigators will conduct a comparative effectiveness study of genotype-supported vs. conventional PPI dosing. Adults and children presenting with Gastroesophageal Reflux Disease (GERD) or dyspepsia symptoms and either 1) being initiated on proton pump inhibitor (PPI) therapy or 2) with continued symptoms on current PPI therapy will be recruited from gastroenterology clinics and randomized to a genotype-supported versus conventional PPI therapy management strategy.
Interventions
- GENETIC CYP2C19 genotyping
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2016-12 |
| Est. Completion | 2019-07-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02930824
The ClinicalTrials.gov registry entry for NCT02930824 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CYP2C19 genotyping is the first listed.
NCT02930824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02930824 about?
NCT02930824 is a clinical study titled "Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing". Investigators will conduct a comparative effectiveness study of genotype-supported vs. conventional PPI dosing. Adults and children presenting with Gastroesophageal Reflux Disease (GERD) or dyspepsia symptoms and either 1) being initiated on proton pump inhibitor (PPI) therapy or 2) with continued s...
What is the current status of trial NCT02930824?
This trial is currently completed. It is a NA study. The enrollment target is 185 participants. The study started on 2016-12. Estimated completion is 2019-07-17.
What interventions are being tested in trial NCT02930824?
The interventions under investigation include: CYP2C19 genotyping (GENETIC).
Who is sponsoring clinical trial NCT02930824?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.